drugset / Trial / NCT05175131
Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders
RandomizedParallel-groupOpen-labelTreatment
Summary
The parallel three-group study of efficacy and safety was planned to investigate the reduction in abdominal pain and bloating during treatment with the fixed-dose combination of Mebeverine + Simethicone versus Duspatalin® and Espumisan® as a monotherapy (Protocol No. MESI3001).
Timeline
- Start
- 2020-11-27
- Primary completion
- 2021-05-18
- Completion
- 2021-05-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mebeverine | Small molecule | 135 mg | Oral |
| Comparator | Simethicone | Other / unclassified | 40 mg | Oral |
| Comparator | Simethicone | Other / unclassified | 80 mg | Oral |